Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

In total, 234 investments creating 13,500 new jobs over the next five years, 59% of which were in regional locations ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings ... Joining me on today's call are Dave Ricks, Lilly's chair and CEO; Dr. Dan Skovronsky, chief scientific officer and ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that ...

While first-generation glucagon-like peptide-1 receptor agonists have clearly taken the obesity market by storm, generating billions of dollars for Novo Nordisk A/S and Eli Lilly and Co., several ...

Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.

"2024 was a highly successful year for Lilly," said Eli Lilly CEO David Ricks in a statement. In addition to success with its weight-loss drugs, Ricks cited "major data readouts for tirzepatide in ...